Veracyte, Inc. (VCYT)

NASDAQ: VCYT · IEX Real-Time Price · USD
17.84
+0.53 (3.06%)
Sep 27, 2022 9:35 AM EDT - Market open
3.06%
Market Cap 1.28B
Revenue (ttm) 268.35M
Net Income (ttm) -48.65M
Shares Out 71.58M
EPS (ttm) -0.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,923
Open 16.55
Previous Close 17.31
Day's Range 17.78 - 18.12
52-Week Range 14.85 - 54.13
Beta 1.18
Analysts Buy
Price Target 30.94 (+73.6%)
Earnings Date Nov 7, 2022

About VCYT

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, incl... [Read more...]

Industry Biotechnology
IPO Date Oct 30, 2013
CEO Bonnie Anderson
Employees 761
Stock Exchange NASDAQ
Ticker Symbol VCYT
Full Company Profile

Financial Performance

In 2021, Veracyte's revenue was $219.51 million, an increase of 86.85% compared to the previous year's $117.48 million. Losses were -$75.56 million, 116.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is 30.94, which is an increase of 73.63% from the latest price.

Price Target
$30.94
(73.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Should Growth Investors Buy This Little-Known Stock?

Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.

3 days ago - The Motley Fool

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

2 weeks ago - Business Wire

New Data Presented at ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Tre...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confir...

2 weeks ago - Business Wire

New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Dise...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitia...

2 weeks ago - Business Wire

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in...

3 weeks ago - Business Wire

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company's genomic tests for prostate (Decipher) and breast (Prosigna) canc...

3 weeks ago - Business Wire

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy i...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data published in Nature Medicine suggest Veracyte's immuno-oncology biomarkers could help predict patient response to immunotherapies.

4 weeks ago - Business Wire

3 Cathie Wood Stocks for the Future

Unlike a lot of tech investors, Cathie Wood is super bullish on biotechnology. Here are three of her picks that these Motley Fool contributors love.

Other symbols: ADPTFATE
1 month ago - The Motley Fool

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

1 month ago - Business Wire

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 38.10% and 8.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Veracyte Announces Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022. “Our second quarter results reflect our continue...

1 month ago - Business Wire

3 Reasons to Buy This Sizzling Growth Stock

Veracyte appears to be an intriguing pick for growth investors to compound their wealth over the long run.

2 months ago - The Motley Fool

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier P...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company's RNA sequencing-based Afi...

2 months ago - Business Wire

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, Au...

2 months ago - Business Wire

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte's Percepta Genomic Sequencing Classifier...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data published in PLOS ONE show Veracyte's Percepta Genomic Sequencing Classifier can improve lung cancer diagnosis in certain lung nodule patients.

2 months ago - Business Wire

Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago - Zacks Investment Research

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year....

3 months ago - Business Wire

New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practice

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifi...

3 months ago - Business Wire

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier fo...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men with Prostate Cancer Progression

3 months ago - Business Wire

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Im...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new data published online in The Lancet Oncology suggest that the company's Immunoscore Immune Checkpoint...

3 months ago - Business Wire

New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the Decipher Prostate gen...

4 months ago - Business Wire

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) as...

4 months ago - Business Wire

Veracyte to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in...

4 months ago - Business Wire

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test's Clinical Performance and Utility in Lung Cancer Ri...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and form...

4 months ago - Business Wire

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Updated AUA/ASTRO Guideline Includes Use of Genomic Tests, Including Decipher Prostate, for Men with Localized Prostate Cancer

4 months ago - Business Wire